10. Use of the compound according to claim 9, in the manufacture of a medicament for the prevention and/or treatment of a disease or disorder modulated by GPR120 and/or GPR40.

11. The use according to claim 10, wherein said disease or disorder is selected from diabetes, preferably type 2 diabetes, impaired oral glucose tolerance, insulin resistance, obesity, obesity related disorders, metabolic syndrome, dyslipidemia, elevated LDL, elevated triglycerides, obesity induced inflammation, osteoporosis and obesity related cardiovascular disorders.

12. A pharmaceutical composition comprising as the active ingredient at least one compound according to any one of claims 1 to 8 in combination with physiologically acceptable excipients.

13. A pharmaceutical composition according to claim 12, suitable to be administered by intravenous, intraperitoneal, inhalation, topical or oral route.

14. A pharmaceutical composition according to claim 12 or 13, in the form of a liquid or a solid, preferably in the form of capsules, tablets, coated tablets, syrup, powders, granules, creams, lotions, sprays or ointments.

15. Use of the compound of formula (I), wherein A is phenyl $R^1$, $R^2$ and $R^3$ are hydrogen, n is 0, and $R^4$ is $–(CH_2)_4–C(O)OH$ in the manufacture of a medicament for the prevention and/or treatment of a disease or disorder modulated by GPR120 and/or GPR40.

16. Use of the compound of formula (I), wherein A is phenyl $R^1$ and $R^2$ are hydrogen, $R^3$ is Cl in position para on the aromatic ring, n is 0, and $R^4$ is $–(CH_2)_4–C(O)OH$ in the manufacture of a medicament for the prevention and/or treatment of a disease or disorder modulated by GPR120 and/or GPR40.

17. The use according to claim 15 or 16, wherein said disease or disorder is selected from diabetes (particularly type 2 diabetes), impaired oral glucose tolerance, insulin resistance, obesity, obesity related disorders, metabolic syndrome, dyslipidemia, elevated LDL, elevated triglycerides, obesity induced inflammation, osteoporosis and obesity related cardiovascular disorders.